Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-04

KRYS vs KYMR: stock comparison and AI forecast

Krystal Biotech, Inc. (KRYS) and Kymera Therapeutics, Inc. (KYMR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Biological Products, (No Diagnostic Substances)

KRYS Krystal Biotech, Inc.

Price
$295.90 +3.1% · 6M
Market Cap
$9.04B
P/E Ratio
41.5x
Size
mid-cap
AI Forecast
Full analysis →
Nasdaq · Biological Products, (No Diagnostic Substances)

KYMR Kymera Therapeutics, Inc.

Price
$127.51 +52.5% · 6M
Market Cap
$10.85B
P/E Ratio
–
Size
large-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

6M · 2026-05-04 → 2026-11-03

Six-month price performance

Closing prices rebased to 100 at the start of the window.

90105120135150
KRYS +3.1% KYMR +52.5%
KRYS · KYMR

Key facts

  • KYMR is 1.2 times larger than KRYS by market capitalization ($10.85B against $9.04B).
  • Over the last six months KYMR returned +52.5% and KRYS +3.1%.
  • KRYS turns 47.9% of its revenue into net income, against -514.8% for KYMR.
  • KRYS carries 0.10 times debt per unit of equity, against 0.09 times for KYMR.
  • Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricKRYSKYMR
Market Cap$9.04B$10.85B
P/E Ratio41.45x–
P/B Ratio6.30x6.72x
EPS$7.36$-3.74
Book Value/Share$48.44$18.91
Revenue/Share$15.86$0.80
FCF/Share$10.46$-3.38

Profitability & Margins

MetricKRYSKYMR
ROE15.7%-21.6%
ROA14.2%-19.8%
ROIC15.8%-24.1%
Gross Margin–0.0%
Operating Margin48.4%-596.6%
Net Margin47.9%-514.8%
EBT Margin55.1%-540.5%
Tax Rate13.0%–

Financial Health

MetricKRYSKYMR
Current Ratio7.89x11.13x
Quick Ratio7.53x–
D/E Ratio0.10x0.09x
Financial Leverage1.10x1.09x
Interest Coverage–-3200.7x
Working Capital$980M$909M

Cash Flow

MetricKRYSKYMR
Operating Cash Flow$324M-$288M
Free Cash Flow$310M-$289M
Capital Spending-$14M-$1M
OCF Growth YoY83.8%–
FCF Growth YoY87.3%–
FCF/Sales66.0%-425.6%
CapEx/Sales3.0%2.0%

Operational Efficiency

MetricKRYSKYMR
Asset Turnover0.30x0.04x
Receivables Turnover3.5x–
Fixed Assets Turnover3.1x1.8x
Days Sales Outstanding103 days–
Payables Period–64 days

Income Statement

MetricKRYSKYMR
Total Revenue$470M$68M
Operating Income$228M-$405M
Net Income$225M-$349M
R&D Expense$60M$430M
SG&A Expense$156M–
Cost of Goods Sold–$68M

Dividend & Shareholder Information

MetricKRYSKYMR
Shares Outstanding30M85M
Net Income Growth13.2%–
EPS Growth1.7%–
FAQ

KRYS vs KYMR: stock comparison and AI forecast

Which is bigger, KRYS or KYMR?

KYMR is 1.2 times larger than KRYS by market capitalization ($10.85B against $9.04B).

Which stock performed better over the last six months, KRYS or KYMR?

Over the last six months KYMR returned +52.5% and KRYS +3.1%.

Which one does Intratio's AI model rank higher, KRYS or KYMR?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.